Oral pharmaceutical composition of isotretinoin

Patent metadata

Field	Value
Publication number	US-9700535-B2
Application number	US-201514958398-A
Country	US
Kind code	B2
Filing date	Dec 3, 2015
Priority date	Jul 31, 2014
Publication date	Jul 11, 2017
Grant date	Jul 11, 2017

Abstract

An oral pharmaceutical composition of isotretinoin with reduced food effect. A process for preparing the oral pharmaceutical composition of the present invention.

First claim

We claim:

1. An oral pharmaceutical composition comprising micronized isotretinoin having d 90 value of not more than 30 microns, wherein said composition is in the form of dispersion in a liquid vehicle and exhibits reduced food effect when administered orally and has a mean fed/fasted ratio of AUC of about 1.26 and a mean fed/fasted ratio of C max of about 1.10.

2. The oral pharmaceutical composition according to claim 1 , wherein said composition comprises:
a) isotretinoin;
b) one or more surfactants having HLB value of 10 or greater; and
c) one or more co-solvents
wherein said composition is substantially free of oil.

3. The oral pharmaceutical composition according to claim 2 , wherein said composition comprises isotretinoin in an amount of about 1 mg to 100 mg, 5 mg to 50 mg, 10 mg to 40 mg, 9 mg to 36 mg, or 8 mg to 32 mg.

4. The oral pharmaceutical composition according to claim 3 , wherein said composition comprises isotretinoin in an amount of about 40 mg, about 36 mg, about 32 mg, about 28 mg, about 24 mg, about 20 mg, about 16 mg, or about 8 mg.

5. The oral pharmaceutical composition according to claim 2 , wherein the surfactant is selected from the group consisting of polysorbates prepared from lauric, palmitic, stearic, and oleic acid; polyoxyethylene monoesters; polyethoxylated castor oils; polyethylene glycol glycerides; Vitamin E TPGS; dioctyl sodium sulfosuccinate; sodium lauryl sulfate; poloxamers; and mixtures thereof.

6. The oral pharmaceutical composition according to claim 5 , wherein the surfactant is present in an amount of about 1% w/w to about 99% w/w by total weight of the composition.

7. The oral pharmaceutical composition according to claim 6 , wherein the surfactant is present in an amount of about 30% w/w to about 80% w/w by total weight of the composition.

8. The oral pharmaceutical composition according to claim 2 , wherein the co-solvent is selected from the group consisting of propylene glycol, polypropylene glycol, polyethylene glycols, diethyleneglycol monoethyl ether, glyceryl caprylate, capric/caprylic glyceride, and mixtures thereof.

9. The oral pharmaceutical composition according to claim 2 , wherein said composition further comprises an antioxidant.

10. The oral pharmaceutical composition according to claim 9 , wherein the antioxidant is selected from the group consisting of butylated hydroxy anisole, butylated hydroxy toluene, tocopherol, ascorbyl palmitate, ascorbic acid, sodium metabisulfite, sodium sulfite, sodium thiosulfate, propyl gallate, and mixtures thereof.

11. The oral pharmaceutical composition according to claim 2 , wherein said composition is in the form of a dispersion which is further filled into capsules.

12. The oral pharmaceutical composition according to claim 1 , wherein the particle size distribution of isotretinoin is such that D 90 is less than 30 μn, less than 25 μm, less than 20 μm, less than 15 μm, or less than 10 μm.

13. The oral pharmaceutical composition according to claim 1 , wherein the particle size distribution of isotretinoin is such that D 50 , less than 20 μm, less than 15 μm, less than 10 μm, or less than 5 μm.

14. The oral pharmaceutical composition according to claim 13 , wherein the particle size distribution of isotretinoin is such that D 50 is less than 15 μm.

15. The oral pharmaceutical composition according to claim 1 , wherein the particle size distribution of isotretinoin is such that D 10 is less than 10 μm, less than 8 μm, less than 7 μm, less than 5 μm, or less than 2 μm.

16. The oral pharmaceutical composition according to claim 15 , wherein the particle size distribution of isotretinoin is such that D 10 is less than 7 μm.

17. The oral pharmaceutical composition according to claim 1 , wherein said composition is stable when stored at 40° C. and 75% relative humidity or at 25° C. and 60% relative humidity for a period of at least three months.

18. The oral pharmaceutical composition according to claim 1 , wherein said composition is used for the treatment of acne, musculoskeletal and connective tissue inflammations, emphysema, ulcerating diseases, cervical tumors in HIV positive women, lung cancer in smokers, skin cancer, neuroblastoma, recurrent prostate cancer, leukemia, high-grade glioma, head and neck cancers, multiple myeloma, gram-negative folliculitis, recalcitrant rosacea, pyoderma faciale, psoriasis, cutaneous lupus erythematosus, acne fulminans, squamous cell carcinoma, or cutaneous photoaging.

19. The oral pharmaceutical composition according to claim 18 , wherein said composition is used for the treatment of acne.

20. The oral pharmaceutical composition according to claim 1 , wherein said composition releases more than 50% of isotretinoin in 15 minutes in a media with a pH of 7.8.

21. A capsule composition of micronized isotretinoin having a d 90 value not more than 30 microns, wherein said composition is in the form of dispersion in a liquid vehicle and exhibits reduced food effect when administered orally and has a mean fed/fasted ratio of C max of about 1.10.

Assignees

• Sun Pharmaceutical Ind Ltd

Inventors

• Rao Rajesh
• Fanda Anuj Kumar
• Jain Satish Kumar
• Singh Romi Barat

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61K31/07

  Retinol compounds, e.g. vitamin A (retinoic acids A61K31/203) · CPC title